Therapeutic drug monitoring market seen topping $4 billion by 2030

The therapeutic drug monitoring market is projected to rise from $2.41 billion in 2025 to $4.09 billion by 2030 as hospitals and labs lean harder into precision medicine and patient-specific dosing. North America leads today, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Therapeutic drug monitoring helps clinicians measure drug levels and adjust dosing to improve safety and effectiveness. - The market is expanding as healthcare systems push harder toward precision medicine, personalized treatment, and tighter control of medicines with narrow therapeutic windows. - Growth in diagnostic testing and real-time monitoring could change how hospitals and labs manage chronic and high-risk therapies.

What happened: - The Business Research Company published its Therapeutic Drug Monitoring Global Market Report 2026, covering market size, trends, and forecast data for 2026-2035. - The report puts the market at $2.41 billion in 2025 and expects it to reach $2.67 billion in 2026. - The report projects the market will reach $4.09 billion by 2030. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to grow the fastest during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The company offers a free sample of the report and the full market report.

The details: - Therapeutic drug monitoring measures drug concentrations in a patient’s bloodstream to keep treatment effective and safe. - The approach is especially useful for drugs with a narrow therapeutic window, highly variable pharmacokinetics, or known therapeutic and adverse effects. - It is also used when close monitoring is needed to avoid toxicity or treatment failure. - The market’s recent growth is tied to broader use of narrow-therapeutic-index drugs, more hospital laboratory testing, wider adoption of immunoassay technologies, higher chronic disease rates, and better analytical instruments. - The report cites rising demand for precision medicine, more automated diagnostic laboratories, more patient-specific dosing, advances in mass spectrometry, and growing use of real-time therapeutic monitoring as major drivers through 2030. - Expected trends include broader LC-MS-based monitoring, more personalized medicine, integration of automated lab systems, expansion of real-time drug level analysis, and greater focus on precise dosing. - The report also highlights deeper market intelligence tools in its 2026 edition, including attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The report points to a market moving from routine monitoring toward data-driven, faster, and more automated testing. - Asia-Pacific’s growth outlook suggests diagnostic capacity and healthcare investment are becoming more important than current market share alone. - A cited UK public health update showed 12,418 young people under 18 accessed alcohol and drug services between April 2022 and March 2023, up 10% from 11,326 the year before, underscoring the need for tighter medication oversight.

What's next: - Demand is likely to keep rising as more health systems adopt precision dosing and real-time monitoring. - Wider use of mass spectrometry and LC-MS-based testing could help push the market toward the report’s 2030 forecast. - Regional growth may increasingly depend on how quickly hospitals and labs in Asia-Pacific add automated diagnostic capacity.

The bottom line: - Therapeutic drug monitoring is moving from a specialist tool to a broader part of precision care, and the market’s growth forecast reflects that shift.